Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review

Colorectal cancer (CRC) continues to be one of the most prevalent and deadliest forms of cancer worldwide, despite notable advancements in its management. The prognosis for metastatic CRC remains discouraging, with a relative 5 -year survival rate for stage IV CRC patients. Conventional treatments f...

Full description

Bibliographic Details
Published in:INTERNATIONAL JOURNAL OF PHARMACEUTICS
Main Authors: Ibrahim, Intan Shazleen; Chellathurai, Melbha Starlin; Mahmood, Syed; Azmi, Amirul Hakim; Harun, Norsyifa; Nazri, Mohd Ulul Ilmie Ahmad; Mahat, Mohd Muzamir; Sofian, Zarif Mohamed
Format: Review; Early Access
Language:English
Published: ELSEVIER 2024
Subjects:
Online Access:https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001154098500001
author Ibrahim
Intan Shazleen; Chellathurai
Melbha Starlin; Mahmood
Syed; Azmi
Amirul Hakim; Harun
Norsyifa; Nazri
Mohd Ulul Ilmie Ahmad; Mahat
Mohd Muzamir; Sofian
Zarif Mohamed
spellingShingle Ibrahim
Intan Shazleen; Chellathurai
Melbha Starlin; Mahmood
Syed; Azmi
Amirul Hakim; Harun
Norsyifa; Nazri
Mohd Ulul Ilmie Ahmad; Mahat
Mohd Muzamir; Sofian
Zarif Mohamed
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review
Pharmacology & Pharmacy
author_facet Ibrahim
Intan Shazleen; Chellathurai
Melbha Starlin; Mahmood
Syed; Azmi
Amirul Hakim; Harun
Norsyifa; Nazri
Mohd Ulul Ilmie Ahmad; Mahat
Mohd Muzamir; Sofian
Zarif Mohamed
author_sort Ibrahim
spelling Ibrahim, Intan Shazleen; Chellathurai, Melbha Starlin; Mahmood, Syed; Azmi, Amirul Hakim; Harun, Norsyifa; Nazri, Mohd Ulul Ilmie Ahmad; Mahat, Mohd Muzamir; Sofian, Zarif Mohamed
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review
INTERNATIONAL JOURNAL OF PHARMACEUTICS
English
Review; Early Access
Colorectal cancer (CRC) continues to be one of the most prevalent and deadliest forms of cancer worldwide, despite notable advancements in its management. The prognosis for metastatic CRC remains discouraging, with a relative 5 -year survival rate for stage IV CRC patients. Conventional treatments for advanced malignancies such as chemotherapy, often face limitations in effectively targeting cancer cells resulting in off -target distribution and significant side effects. In the quest for better strategies, researchers have explored numerous alternatives. Among these, nanoparticles (NPs) specifically liposomes have emerged as one of the most promising candidates in developing targeted delivery systems for cancer therapeutics. This review discusses the current approaches employing functionalised liposomes to overcome major biological barriers in therapeutics delivery for CRC treatment. We have also shared our perspectives on the technological development of liposomes for future clinical use and highlighted a few useful insights on the material choices for future research work in CRC.
ELSEVIER
0378-5173
1873-3476
2024
651

10.1016/j.ijpharm.2023.123735
Pharmacology & Pharmacy

WOS:001154098500001
https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001154098500001
title Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review
title_short Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review
title_full Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review
title_fullStr Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review
title_full_unstemmed Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review
title_sort Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review
container_title INTERNATIONAL JOURNAL OF PHARMACEUTICS
language English
format Review; Early Access
description Colorectal cancer (CRC) continues to be one of the most prevalent and deadliest forms of cancer worldwide, despite notable advancements in its management. The prognosis for metastatic CRC remains discouraging, with a relative 5 -year survival rate for stage IV CRC patients. Conventional treatments for advanced malignancies such as chemotherapy, often face limitations in effectively targeting cancer cells resulting in off -target distribution and significant side effects. In the quest for better strategies, researchers have explored numerous alternatives. Among these, nanoparticles (NPs) specifically liposomes have emerged as one of the most promising candidates in developing targeted delivery systems for cancer therapeutics. This review discusses the current approaches employing functionalised liposomes to overcome major biological barriers in therapeutics delivery for CRC treatment. We have also shared our perspectives on the technological development of liposomes for future clinical use and highlighted a few useful insights on the material choices for future research work in CRC.
publisher ELSEVIER
issn 0378-5173
1873-3476
publishDate 2024
container_volume 651
container_issue
doi_str_mv 10.1016/j.ijpharm.2023.123735
topic Pharmacology & Pharmacy
topic_facet Pharmacology & Pharmacy
accesstype
id WOS:001154098500001
url https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001154098500001
record_format wos
collection Web of Science (WoS)
_version_ 1809678633513517056